US2008221309A1PendingUtilityA1

MN Gene and Protein

57
Assignee: ZAVADA JANPriority: Mar 11, 1992Filed: Oct 31, 2007Published: Sep 11, 2008
Est. expiryMar 11, 2012(expired)· nominal 20-yr term from priority
A61P 35/00A61P 43/00C07K 14/82C07K 16/08C07K 2319/00A61K 39/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements.

Claims

exact text as granted — not AI-modified
1 - 37 . (canceled) 
     
     
         38 : A biologically active recombinant antibody or biologically active recombinant antibody fragment which specifically binds to an MN protein or to an MN polypeptide, wherein said MN protein or MN polypeptide is encoded by a nucleic acid selected from the group consisting of:
 (a) SEQ ID NO: 1;   (b) nucleotide sequences that are 80% homologous to SEQ ID NO: 1; and   (c) nucleotide sequences that differ from SEQ ID NO: 1 or from the nucleotide sequences of (b) due to the degeneracy of the genetic code;   wherein said antibody or antibody fragment is conjugated to a functional moiety.   
     
     
         39 : The antibody or antibody fragment of  claim 38 , wherein the functional moiety is selected from the group consisting of a chemotherapeutic drug, a toxic agent, a cytokine, and a label. 
     
     
         40 : The antibody or antibody fragment of  claim 38 , wherein the functional moiety is a chemotherapeutic drug or toxic agent. 
     
     
         41 : The antibody or antibody fragment of  claim 38 , wherein the functional moiety is ricin A.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.